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levels of So are regulated by ceramidases, a group of amido-
hydrolases that catalyze the hydrolysis of ceramides (Cers) 
into So and fatty acids (4). According to their optimum 
pH, ceramidases are classified as acid, neutral, or alkaline. 
They differ in their primary structures because they are 
coded by different genes. The five human ceramidases de-
scribed so far, one acidic [acidic ceramidase (AC)], one 
neutral [neutral ceramidase (NC)], and three alkaline 
[alkaline ceramidases (ACERs)] differ also on their tissue 
distribution (5). Thus, while AC is ubiquitously expressed, 
NC is highly expressed in the small intestine, while the three 
ACERs are exclusively expressed in the skin cells. Very 
recently, the structure of ACER3 has been disclosed (6). 
Apart from their optimum pH, ceramidases show different 
selectivity for Cers depending on the length and degree of 
saturation of the N-acyl side chain (4). Thus, AC prefers 
C12 and C14 Cers and NC prefers C16 and C18 Cers, while 
ACER1 prefers C20 to C24 chains (7). The remaining 
ACERs are less selective, because ACER2 deamidates Cers 
with saturated acyl chains (8) as well as dihydroceramides 
(dhCers) with C18 and C20 monounsaturated chains (9), 
while ACER3 also hydrolyzes phytoceramides with unsatu-
rated acyl chains (10).
The role of some CDases as therapeutic targets (4) raises 
the interest for selective CDase inhibitors and, hence, 
the development of efficient protocols amenable to high-
throughput screening (HTS) formats. In this context, in 
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Besides their classically accepted role as structural cell 
components, sphingolipids are also a well-recognized 
group of bioactive lipids with significant implications in 
cell signaling and disease (1). This is the basis of the so-
called sphingolipid rheostat, in which the relative levels of 
sphingosine (So) and sphingosine-1-phosphate (S1P) dic-
tate the cell fate (2). Thus, while S1P results from phos-
phorylation of So by specific kinases (3), the intracellular 
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previous works (11, 12), a series of first generation fluo-
rogenic substrates (RBM14) with different N-acyl chains 
(from C8 to C16) were described as efficient CDase sub-
strates with different selectivities. However, while RBM14C12 
has been characterized as an efficient AC substrate (11, 
13), the remaining substrates proved less selective toward 
NC, another interesting therapeutic target (14) for which 
no selective inhibitors have been developed so far. More-
over, selective substrates for the ACERs (ACER1–3) are 
also lacking.
Considering the above precedents and given our contin-
ued interest in the development of selective probes for the 
different ceramidases, we want to report on a series of new 
fluorogenic substrates derived from our previously re-
ported RBM14 probes (11–13), as well as new probes de-
rived from a homologated version thereof (RBM15) that 
also incorporates the 2-(N-acylamino)-1,3-diol-4-ene frame-
work present in the natural Cers (Fig. 1).
In order to widen the scope of our previously reported 
RBM14 probes (11–13), longer and/or unsaturated N-acyl 
chain amides have been used in this study, in particular 
those from oleic acid (C18:1-9), erucic acid (C22:1-9), 
and nervonic acid (C24:1-9). In addition, results from a 
recent report seem to indicate that ACER1/ cells accu-
mulate -hydroxy eicosanoic Cer (15). Because this obser-
vation can be related with a higher selectivity of ACER1 
toward this type of side chain, we have also synthesized the 
corresponding (R)- and (S)-N-(-hydroxyeicosanoyl) am-
ides. For the sake of comparison, the same N-acyl substitu-




The required carboxylic acids [oleic, erucic, nervonic, and 
(±)--hydroxyeicosanoic] were obtained from commercial 
sources. DMEM, FBS, methyl--cyclodextrin (MBCD), and tetra-
cycline were from Sigma. Zeocin was from Genaxxon Bioscience 
and blasticidin from CalBiochem. Opti-MEM and lipofectamine 
2000 were from Invitrogen. Recombinant human NC was ob-
tained from R&D Systems. pCMV6 plasmid harboring the mouse 
Acer3 (MR218055) was from OriGene and the plasmid harboring 
ASAH2 was kindly provided by Dr. Daniel Canals and Prof. Yussuf 
Hannun (Department of Medicine, State University of New York 
at Stony Brook, Stony Brook, NY).
Synthesis
The probes described in this work were obtained by acyla-
tion of RBM14 (11) or RBM15 with the suitable carboxylic 
acid. Probe RBM15 was obtained from deprotection of the 
corresponding N-Boc precursor (RBM15-N-Boc), obtained as 
described in (16).
Deprotection of RBM15-N-Boc. A solution of the starting mate-
rial (382 mg, 942.2 mol) in methanol (60 ml) was treated with 
CH3COCl (500 l, 27.6 mmol) and the reaction was stirred at 
room temperature overnight. The mixture was concentrated in 
vacuo and the resulting crude was flash chromatographed (silica gel) 
with a step gradient of DCM/methanol (from 0% to 5% metha-
nol at 1% increments). Compound RBM15 (262 mg, 855 mol, 
91% yield) was obtained as a yellow oil; TLC (DCM:methanol, 9:1; 
Rf: 0.13); []D
25: 3.86 (c 1.0, methanol). IR:  3,322 (O-H and 
N-H), 2,934 (CH3), 1,698 (C=O, ester); 
1H NMR (CD3OD, 400 
MHz):  7.89 (d, J = 9.5 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 6.97-6.89 
(m, 2H), 6.25 (d, J = 9.5 Hz, 1H), 5.97 (dtd, J = 15.2, 6.8, 1.3 Hz, 
1H), 5.67 (ddt, J = 15.5, 6.6, 1.5 Hz, 1H), 4.34 (ddd, J = 6.1, 4.7, 
1.2 Hz, 1H), 4.16 (t, J = 6.4 Hz, 2H), 3.81 (dd, J = 11.6, 4.1 Hz, 
1H), 3.68 (dd, J = 11.6, 8.2 Hz, 1H), 3.23 (dt, J = 8.6, 4.4 Hz, 1H), 
2.65-2.57 (m, 2H); 13C NMR (CDCl3, 400 MHz):  163.64, 163.31, 
156.86, 145.79, 131.50, 131.31, 130.46, 114.04, 113.91, 113.22, 
102.19, 70.77, 68.83, 59.48, 58.31, 32.92.
HRMS. Calculated for C16H20NO5
+ [M+H]+: 306.1341; Found: 
306.1328.
General method for acylation of RBM14 and RBM15. A solution 
of HOBt (40 mg, 285.3 mol), the corresponding carboxylic 
acid (280 mol), and EDC (70 mg, 380.4 mol) in anhydrous 
DCM (5 ml) was added dropwise to a solution of RBM14 
or RBM15 (190 mol) in DCM (5 ml) and Et3N (100 l, equiva-
lent to 717 mol) under argon atmosphere. For the amides of 
(±)--hydroxyeicosanoic acids, the solution of EDC and HOBt 
was added dropwise over a mixture of the starting amine and the 
carboxylic acid. In all cases, the reaction mixture was stirred at 
room temperature overnight, and the mixture was concentrated in 
vacuo. The resultant crude was flash-chromatographed (silica gel) 
Fig. 1. Probes described in this work.
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using a step gradient of DCM/methanol (from 0% to 3% metha-
nol at 1% increments). The required amides were obtained as oils 
or waxy solids. Full characterization and NMR spectra can be found 
in the supplemental data.
Cells
The FD-AC cell line stably overexpressing AC (provided by 
Prof. Thierry Levade, INSERM UMR1037 CRCT, Toulouse, 
France), HeLa T-Rex ACER1-TET-ON, HeLa T-Rex ACER2-TET-
ON, HEK293T, and HT29 cells were cultured at 37°C in 5% CO2 
in DMEM medium supplemented with 10% FBS. The antibiotic 
selection of HeLa T-Rex TET-ON cells was performed with zeocin 
(25 g/ml) and blasticidin (5 g/ml). These antibiotics were 
removed during treatments.
Enzyme source
Experiments with AC were performed in lysates of the FD-AC 
cell line stably overexpressing ASAH1. NC experiments were car-
ried out in recombinant human NC and in HT29-overexpressing 
NC cells. To overexpress human NC, HT29 cells were transfected 
with 2.5 g/well of a plasmid harboring the ASAH2 gene using 5 
l/well lipofectamine and Opti-MEM, following the manufactur-
er’s instructions. Then, tetracycline (0.05 M) was added for 24 h 
before use. In the case of ACERs, microsomes from three differ-
ent cell lines were used. To overexpress mouse ACER3, HEK293T 
cells were transfected with 2.5 g/well of a plasmid harboring the 
mouse ACER3 gene using 5 l/well lipofectamine and Opti-
MEM, following the manufacturer’s instructions. To overexpress 
ACER1 and ACER2, tetracycline (0.05 M) was added to HeLa 
T-Rex TET-ON cells for 24 h before use.
Cell lysates
Cell pellets were resuspended in the appropriate volume of a 
0.25 M saccharose solution with the protease inhibitors, aprotinin 
(1 mg/ml), leupeptin (1 mg/mml), and PMSF (100 mM). The 
suspension was submitted to three cycles of a 5 s sonication 
(probe) at 10 watts/5 s resting on ice. The cell lysate was centri-
fuged at 600 g for 5 min. The supernatant was collected, and pro-
tein concentration was determined as specified below.
Microsomal preparations
Cell lysates obtained from HeLa T-Rex ACER1-TET-ON, HeLa 
T-Rex ACER2-TET-ON, and HEK293T-overexpressing ACER3 
cells were transferred to ultracentrifuge tubes and spun at 100,000 
g for 1 h at 4°C. Pellets were resuspended in a 0.25 M saccharose 
solution and protein concentration was determined as specified 
below.
Determination of protein concentration
Protein concentrations were determined with BSA as a stan-
dard using a BCA protein determination kit (Thermo Scientific) 
according to the manufacturer’s instructions.
Ceramidase activities
Activity assays were carried out in 96-well plates at a final vol-
ume of 100 l/well. Reaction buffers were: 25 mM sodium acetate 
buffer pH 4.5 (AC); 50 mM HEPES, 150 mM NaCl, and 1% so-
dium cholate (NaChol) pH 7.4 (NC); and 50 mM HEPES and 
1 mM CaCl2 pH 9 (ACERs). The reaction mixtures contained 
25 l/well of protein (recombinant NC or cell lysate) and 75 l/well 
of substrate. Substrates were tested at 40 M concentration, pre-
pared from 4 mM stock solutions in ethanol. The reaction mix-
ture was incubated at 37°C for 3 h, except for the determination 
of KM and Vmax parameters (between 20 and 60 min, depending 
on the substrate). For the determination of ceramidase activity 
with RBM14 substrates, reactions were stopped with 25 l/well of 
methanol and then 100 l/well of NaIO4 (2.5 mg/ml in glycine-
NaOH buffer, pH 10.6) were added. After incubation at 37°C for 
30 min in the dark, 100 l/well of 0.1 M glycine-NaOH buffer 
(pH 10.6) were added. To determine ceramidase activity with 
RBM15 substrates, reactions were stopped with 50 l/well of 
NaIO4 (2.5 mg/ml in methanol) and then 100 l/well of KOH-
methanol were added (0.1 M KOH-methanol solution in the case 
of NC and ACERs or 0.2 M KOH-methanol for AC). After incuba-
tion at 37°C for 30 min in the dark, 50 l/well of 0.1 M glycine-
NaOH buffer (pH 10.6) were added. In all cases, fluorescence was 
measured spectrophotometrically at excitation and emission 
wavelengths of 355 and 460 nm, respectively. The same reaction 
mixtures without enzymes were used as blanks.
Ceramidase activity in intact cells
To determine ceramidase activity in intact cells, 5 × 105 cells 
per well were seeded in a 12-well plate. HT29 cells were trans-
fected with 1 g/well of a plasmid harboring the ASAH2 gene 
using 2 l/well lipofectamine and Opti-MEM, following the 
manufacturer’s instructions. Then tetracycline (0.05 M) was 
added for 24 h before use. Medium was replaced by MBCD at 1, 
5, and 10 mM in DMEM with NaChol (500 M) for 30 min. 
Then RBM14-C24:1 was added at a final concentration of 40 
M. The plate was incubated for 3 h at 37°C in 5% CO2. The 
reaction was stopped with 125 l/well of methanol and then 
500 l/well of NaIO4 (2.5 mg/ml in glycine-NaOH buffer, pH 
10.6) were added. After incubation at 37°C for 1 h in the dark, 
500 l/well of 0.1 M glycine-NaOH buffer (pH 10.6) were 
added and fluorescence was measured spectrophotometrically 
at excitation and emission wavelengths of 355 and 460 nm, re-
spectively. The same reaction mixtures without cells were used 
as blanks.
Statistics
Comparison between two means has been carried out with the 
unpaired two-tailed t-test and statistical differences are marked 
with asterisks. For comparison of more than two means, data have 
been analyzed by one-way ANOVA followed by Bonferroni’s mul-
tiple comparison test. Statistical differences between means are 
pointed out with different letters atop each bar (same letter indi-
cates no statistical difference).
RESULTS
Design and synthesis of the probes
Probes RBM14 were obtained by N-acylation of the free 
base with the required carboxylic acids, following previ-
ously reported protocols (12, 13). Probes RBM15 were 
inspired in our “second generation” probes for S1P lyase, 
in which the installation of a vinyl unit between the amino 
diol moiety and the umbelliferone reporter led to a signifi-
cant increase of affinity, probably due to the closer similar-
ity of the vinylogated probe with the natural substrate (16). 
The retro oxa-Michael reaction required for the release of 
the fluorescent reporter from probes RBM15 can be pro-
moted under basic conditions (see below) by abstraction of 
one of the -protons of the intermediate aldehyde RBM7-
083 (16) resulting from NaIO4 oxidation of the amino diol 
RBM15 arising from hydrolysis of the probe by the target 
ceramidase (Fig. 2).
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Optimization conditions for umbelliferone release
Unlike our previously reported protocol with substrates 
RBM14 (11–13), the standard Gly-NaOH buffer (pH 10.6) 
proved inefficient to promote the complete release of the 
umbelliferone from the transient aldehyde RBM7-083 aris-
ing from oxidation of the aminodiol RBM15 (Fig. 2). 
Harsher basic conditions were required in this case to 
ensure acceptable levels of umbelliferone. The opti-
mized conditions from RBM15 required the use of 0.2 
M KOH-methanol (for AC) or 0.1 M KOH-methanol 
(for NC and ACERs), followed by a 30 min incubation at 
37°C in the dark, prior to the addition of 0.2 M glycine-
NaOH buffer (pH 10.6) (50 l/well). However, even 
under these optimized conditions, a fluorescence of 
around 65% of the theoretical maximum was observed 
(supplemental Fig. S2).
Probes RBM14 and RBM15 as AC substrates
Probes RBM14 and RBM15 (Fig. 1) were tested as AC 
substrates in FD-AC cell lysates overexpressing AC. These 
probes were compared with RBM14C12, reported as AC 
substrate in previous work (12, 13). None of the new 
RBM14 probes were superior to RBM14C12 as AC sub-
strates in lysates from FD-AC cells, as evidenced by the fluo-
rescence values observed for the released umbelliferone 
(Fig. 3A). This was also true for probes RBM15, because 
RBM15C16, the best AC substrate of this series, gave values 
around three times lower than those from RBM14C12 (Fig. 
3B). These results are in agreement with the known prefer-
ence of AC for C12–C14 Cers (7) and also with the fact that 
long-chain Cers are not AC substrates (17).
Probes RBM14 and RBM15 as NC substrates
Probes RBM14 and RBM15 were tested as substrates in 
human recombinant NC and HT29 cell lysates overexpress-
ing NC and compared with RBM14C16, which was reported 
in a previous article as the most efficient NC substrate 
among the RBM14 probes (12). In all the experiments, 
similar results were obtained with recombinant NC (Fig. 
3C, D) and with cell lysates (Fig. 3E, F), although the cor-
responding C16 and C18:1 probes of both series (RBM14 
and RBM15) were somewhat better substrates in cell ly-
sates, in comparative terms with the remaining probes. The 
kinetic parameters in human recombinant NC are shown 
in Table 1. Among RBM14 substrates, RBM14C24:1 proved 
slightly superior in terms of affinity (KM) and efficiency 
(Kcat). The preference of human recombinant NC for this 
N-acyl side chain was surprising, given the preference of 
the enzyme for C16 and C18 Cers (7, 18). On the other 
hand, the vinylogated probes RBM15 showed a slightly 
lower affinity in comparison with the corresponding 
RBM14 probes, albeit with similar or even superior Kcat/KM 
parameters. Interestingly, despite the vinylogated probes 
RBM15 being generally well tolerated by human recom-
binant NC, a striking drop in affinity was observed for 
RBM15C16, with KM >250. Finally, both (R)- and (S)--
hydroxyeicosanoyl amides were well tolerated by NC, which 
showed a slight selectivity, in terms of Kcat, for the (R) iso-
mer in the RBM15 series.
Probes RBM14 and RBM15 as ACER substrates
Three different ACERs have been reported with an opti-
mum activity at around pH 9. Because NC exhibits some 
residual CDase activity at basic pH, ACER-overexpressing 
systems were used to test the ability of our probes to act as 
ACER substrates. In a previous work (12), we showed that 
RBM14 probes of short to medium N-acyl chain lengths 
(C8 to C16) were inactive as ACER1 and ACER2 substrates, 
showing only a moderate activity as ACER3 substrates. In 
this work, RBM14 analogs with longer saturated or unsatu-
rated N-acyl chains were devoid of activity as substrates 
toward all three ACER-overexpressing systems (Fig. 4; sup-
plemental Fig. S3A, C, E). However, the vinylogated probes 
RBM15 have been revealed as new ACER1 and ACER2 sub-
strates, being practically inactive toward ACER3. Only 
RBM15C16 behaved as an ACER3 substrate, although 
weaker than its RBM14 counterpart (Fig. 3; supplemental 
Fig. S3B, D, F). Overall, probes RBM15 having a long 
unsaturated N-acyl chain (18:1 and 22:1) can be used as 
substrates to determine ACER1 and ACER2 activities.
Selectivity of probe RBM14C24:1 for NC
The probe RBM14C24:1 turned out to be one of the best 
substrates in kinetic terms on the recombinant human NC 
(Fig. 5) with the lowest KM and a high Kcat/KM ratio, com-
pared with the rest of substrates tested (Table 1), and a 
high selectivity for NC (Fig. 5A). The above promising re-
sults prompted us to test this substrate in intact HT29 cells. 
However, no activity was observed after the initial assays 
(results not shown), which was attributed to the inability 
of the probe to cross the cell membrane. Encapsulation 
into liposomes, similarly as reported by us for a related 
probe (16), was not feasible due to the low solubility of 
RBM14C24:1 in the required solvent system. Gratifyingly, 
the use of MBCD, a well-known system used to increase the 
solubility of nonpolar substances, such as fatty acids, lipids, 
Fig. 2. Metabolic degradation of probes RBM15 and 
release of umbelliferone after oxidation of the free 
base and treatment of the transient aldehyde RBM7-
083 with a base.
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vitamins, and cholesterol, in several cell culture applica-
tions (19) proved efficient to allow the use of RBM14C24:1 
as NC substrate in intact cells (Fig. 5B). A concentration-
dependent effect for MBCD was observed, and an optimal 
concentration of 5 mM could be established.
DISCUSSION
Cer is considered the hub of the intricate set of pathways 
that are implicated in the biosynthesis and degradation of 
sphingolipids (20). Apart from the biosynthesis from sim-
ple structural moieties in the so-called de novo pathway, 
Cer can also be generated by the degradation of complex 
sphingolipids. Moreover, Cer, as well as dhCer (21), can 
also be degraded by CDases, a type of amido hydrolases 
that selectively convert Cers and dhCers into So and sphin-
ganine, respectively, by hydrolysis of the N-fatty acyl chain 
present in the above sphingolipids. Interestingly, the re-
moval of the N-acyl chain is important not only to control 
the relative levels of sphingolipids inside the cell but also to 
dramatically alter their intracellular mobility as a result of 
Fig. 3. Determination of AC (A, B) and NC (C–F) activity using RBM14 and RBM15 substrates. AC activity was measured in cell lysates from 
FD-AC-overexpressing cells. Incubations were carried out with RBM14 (A) or RBM15 (B) substrates in 25 mM sodium acetate buffer pH 4.5. 
NC activity was measured in recombinant NC (C, D) or cell lysates from HT29 control cells (L2000) and HT29 overexpressing ASAH2 (NC) 
(E, F). Incubations were carried out with RBM14 (C, E) or RBM15 (D, F) substrates in 50 mM HEPES, 150 mM NaCl, and 1% sodium cholate 
pH 7.4. New RBM14 substrates were compared with RBM14C12 (for AC) and RBM14C16 (for NC). Data correspond to the mean ± SD of at 
least three different experiments with triplicates.
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the changes in the physical properties after N-deacylation 
(22). Among the different CDases, overexpression of NC 
has been implicated in colon carcinogenesis (14) and, 
hence, has emerged as a new therapeutic target. In this 
context, the discovery of selective inhibitors of this enzyme 
should be boosted by the development of efficient sensitive 
analytical methods amenable for HTS protocols. Based on 
our previous works addressed at the development of fluo-
rogenic probes for CDases (11–13), we were interested in 
expanding the scope and selectivity of our first generation 
probes (RBM14) by using alternative N-acyl chains, based 
on the reported preferences of CDases for the different 
N-acyl Cers. Based on these premises, a collection of poten-
tial RBM14 substrates has been synthesized and tested on 
our different CDase models. Interestingly, despite NC be-
ing selective for C16 and C18 Cers (10), the N-acyl unsatu-
rated probe RBM14C24:1 emerged as the first selective NC 
substrate for recombinant human NC (Table 1, Fig. 5A). 
Moreover, by using MBCD as adjuvant, this substrate is also 
suitable to measure NC activity in intact cells. The fact that 
the C24:1 acyl chain of nervonic acid increases the selectivity 
of RBM14 probes toward NC is in full agreement with the 
reported structural data for this enzyme in which a 20 Å 
deep hydrophobic active site pocket determines the higher 
selectivity of NC toward long-chain acyl Cer substrates (23). 
TABLE 1. Kinetic parameters for the NC catalyzed hydrolysis of 
substrates RBM14 and RBM15
Probe KM Kcat Kcat/KM
RBM14C16 16 ± 3.3a 3,281 ± 298 205.1
RBM14C18:1 28 ± 3.0 432 ± 64 15.4
RBM14C20(S)OH 14 ± 0.2 3,075 ± 61 219.6
RBM14C20(R)OH 16 ± 1.7 2,655 ± 317 165.9
RBM14C22:1 28 ± 6.5 1,397 ± 219 49.9
RBM14C24:1 8 ± 1.7 1,581 ± 100 197.6
RBM15C16 > 250 — —
RBM15C18:1 139 ± 7.2 3,761 ± 465 27.1
RBM15C20(S)OH 21 ± 1.9 7,257 ± 1,092 345.6
RBM15C20(R)OH 42 ± 0.02 22,954 ± 1,004 546.5
RBM15C22:1 33 ± 1.7 4,977 ± 515 150.8
RBM15C24:1 40 ± 0.9 8,415 ± 1,282 210.4
KM is given in micromol, Kcat as 10
3 s1, and Kcat/KM as M
1 s1. 
Recombinant NC (5 ng) was incubated between 20 and 60 min 
(depending on the substrate) at graded concentrations. Experiments 
were carried out as described in the methodology. Data are mean ± SD 
of three to five independent experiments with triplicates.
a See (12).
Fig. 4. Determination of ACER1 (A), ACER2 (B), and ACER3 (C) activity using RBM14 and RBM15 substrates. A: ACER1 activity was 
measured in microsomes isolated from mouse HeLa T-Rex ACER1-TET-ON cells grown in the absence or presence of tetracycline (10 ng/ml) 
for 24 h. Incubations were carried out with RBM14 or RBM15 substrates in 50 mM HEPES buffer with 1 mM CaCl2 at pH 9. B: ACER2 activ-
ity was measured in microsomes isolated from human HeLa T-Rex ACER2-TET-ON cells grown in the absence or presence of tetracycline 
(10 ng/ml) for 24 h. Incubations were carried out with RBM14 or RBM15 substrates in 50 mM HEPES buffer with 1 mM CaCl2 at pH 9. C: 
ACER3 activity was measured in microsomes isolated from mouse HEK293T control cells or HEK293T ACER3-overexpressing cells. Incuba-
tions were carried out with RBM14 or RBM15 substrates in 50 mM HEPES buffer with 1 mM CaCl2 at pH 9. Hydrolysis of RBM14C16 (12) by 
the different ACERs is also shown for comparison. Data correspond to the mean ± SD of at least three different experiments with triplicates. 
Data correspond to difference between control cells and ACER-overexpressing cells (see also supplemental Fig. S3).
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Based on these considerations, the C24:1 acyl chain would 
be too long to fit into the 13 Å cavity found in the AC active 
site (24).
To further expand the applicability of our probes, we 
designed a second generation set of potential substrates 
(compounds RBM15, see Fig. 1). As a differential feature, 
these modified substrates incorporate the characteristic 
C4-C5 vinyl unit present in the natural Cers. Because 
probes RBM15 can be regarded as the vinylogated analogs 
of probes RBM14, their design also fits into the essence of 
the well-established principle of vinylogy (25). In our effort 
to find selective CDase substrates, probes RBM15 were 
tested in our five CDase models and compared with the 
corresponding RBM14 counterparts. The most interesting 
results were obtained with probes RBM15 having long un-
saturated N-acyl chains (18:1 and 22:1), which behaved as 
useful ACER1 and ACER2 substrates (Fig. 4A, B) and were 
totally devoid of activity on AC (Fig. 3A, B) and ACER3 
(Fig. 4C). Because RBM15C18:1 showed much weaker ac-
tivity as NC substrate (Fig. 3C-F), this probe has emerged as 
the best fluorogenic probe reported so far to measure 
ACER1 and ACER2 activities in a 96-well plate format. Al-
though less studied than other CDases, recent studies have 
shown the implication of ACER1 in mammalian skin ho-
meostasis and whole-body energy homeostasis (26) and 
that of ACER2 in DNA damage (27) and cell differentia-
tion processes (28).
In summary, the fluorogenic probes reported in this 
work complement our previously reported probe for AC 
(RBM14C12) (11–13) by enlarging the scope of applicabil-
ity with the discovery of RBM14C24:1 as a highly selective 
probe for NC and probe RBM15C18:1 for ACER1 and 
ACER2 with very low NC activity. These results represent a 
valuable addition to the available toolkit of fluorogenic 
CDase substrates and may enable the development of effi-
cient HTS protocols for the screening of potential selective 
inhibitors of this relevant group of amidohydrolases.
The authors acknowledge the experimental contributions from 
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